Chemopreventive and chemotherapeutic effect of trans-resveratrol and its analogues in cancer;DziaŁanie chemoprewencyjne i terapeutyczne trans-resweratrolu i jego analogów w chorobach nowotworowych

Polski Merkuriusz Lekarski

Volumn 28, Issue 168, 2010, Pages 496-500

  Renata, Mikstacka ^a,b   Ewa, Ignatowicz ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Department of Chemical Technology of Drugs ^*  (United States)

Author keywords

Cancer therapy; Chemoprevention; Trans resveratrol

Indexed keywords

ANTINEOPLASTIC AGENT; RESVERATROL; STILBENE DERIVATIVE;

ANIMAL; ARTICLE; HUMAN; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; NEOPLASMS; STILBENES;

EID: 77954685635     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Almeida L., Vaz-da-Sirva M., Falcao A. i wsp.: Pharmacokinetic and safety profile of trans-resveratrol in ä rising multiple-dose study in healthy volunteers. Mol. Nutr. Food Res., 2009, 53, S7-S15.
2. Athar M., Back J.H., Tang X. i wsp.: Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol., 2007, 224, 274-283.
3. Baur J.A., Sinclair D.A.: Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov., 2006, 5, 493-506.
4. Bishayee A.: Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev. Res., 2009, 2, 409-418.
5. Bisht K., Wagner K.-H., Bulmer A.C.: Curcumin, resveratrol and flavonoids as anti-inflammatory, cyto- and DNA-protective dietary compounds. Toxicology, 2009, doi:10.1016/j.tox.2009.11.008.
6. Boocock D.J., Patel K.R., Faust G.E.S. i wsp.: Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J. Chromatogr., 2007, 848, 182-187.
7. Bove K., Lincoln D.W., Tsan M.-F.: Effect of resveratrol on growth of 4T1 breast cancer cells in vitro and in vivo. Biochem. Biophys. Res. Commun., 2002, 291, 1001-1005.
8. Chaudhary A., Pandeya S.N., Kumar P. i wsp. Combretastatin A-4 analogs as anticancer agents. Mini-Rev. Med. Chem., 2007, 7, 1186-1205.
9. Cichocki M., Paluszczak J., Szaefer H. i wsp.: Pterostilbene is equally potent as resveratrol in inhibiting 12-O-tetradecanoylphorbol-13-acetate activated NFKB, AP-1, COX-2, and iNOS in mouse epidermis. Mol. Nutr. Food Res., 2008, 52, S62-S70.
10. Ferrer P., Asensi M., Segarra R. i wsp.: Association between pterostilbene and quercetin inhibits metastatic activity of B16 melanoma. Neoplasia, 2005, 7, 37-47.
11. Fulda S., Debatin K.M.: Resveratrol modulation of signal transduction in apoptosis and cell survival: a mini review. Cancer Detect. Prev., 2006, 30, 217-223.
12. Han W., Pentecost B.T., Spivack S.D.: Functional evaluation of novel single nucleotide polymorphism and haplotypes in the promoter regions of CYP1B1 and CYP1A1 genes. Mol. Carcinog., 2003, 37, 158-169.
13. Hong Y.B., Kang H.J., Kim H.J. i wsp.: Inhibition of cell proliferation by a resveratrol analog In human pancreatic and breast cancer cells. Exp. Mol. Med., 2009, 41, 151-160.
14. Ignatowicz E., Baer-Dubowska W.: Resveratrol, a natural chemopreventive agent against degenerative diseases. Pol. J. Pharmacol., 2001, 53, 557-569.
15. Ignatowicz E., Baiana B., Vulimiri S.V. i wsp.: The effect of plant phonetics on the formation of 7, 12-dimethylbenz[a]anthracene-DNA adducts and TPA-stimulated polymorphonuclear neutrophils chemiluminescence in vitro. Toxicology, 2003, 189, 199-209.
16. Jang M., Cai L., Udeani G.O. i wsp.: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 1997, 275, 218-220.
17. Kundu J.K., Surh Y-J.: Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett., 2008, 269, 243-261.
18. Lin H.-S., Tringali C., Spatafora C. i wsp.: A simple and sensitive HPLC-UV method for the quantification of piceatannol analog trans-3,5,3',4'- tetramethoxystilbene in rat plasma and its application for a pre-clinlcal pharmacokinetic study. J. Pharmaceut. Biomed. Anal., 2010, 51, 679-684.
19. Markus M.A., Morris B.J.: Resveratrol in prevention and treatment of common clinical conditions of aging. Clin. Interv. Aging, 2008, 3, 331-339.
20. Mikstacka R., Przybylska D., Rimando A.M. i wsp. Inhibition of human recombinant cytochromes P450 CYP1A1 and CYP1B1 by trans-resveratrol methyl ethers. Mol. Nutr. Food Res., 2007, 51, 517-524.
21. Mikstacka R., Baer-Dubowska W., Wieczorek M. i wsp. Thiomethytstilbenes as inhibitor sof CYP1A1, CYP1A2, and CYP1B1 activities. Mol. Nutr. Food Res., 2008, 52, S77-S83.
22. Mikstacka R., Rimando A.M., Ignatowicz E. Antioxidant effect of transresveratrol, pterostilbene, quercetin and their combination in human erythrocytes in vitro. Plant Foods Hum Nutr. 2010, 65, 57-63.
23. Pan M.H., Gao J.H., Lai C.S. i wsp.: Antitumor activity of 3,5,4'-trimethoxystilbene in COLO 205 cells and xenografts In CSID mice. Mol. Carcinogen., 2008, 47, 184-196.
24. Park H, Aiyar S.E., Fan P. I wsp.: Effects of tetramethoxystilbene on hormone-resistant breast cancer cells: biological and biochemical mechanisms of action. Cancer Res., 2007, 67, 5717-5726.
25. Remsberg C.M. Yanez J.A., Ohgami Y. i wsp.: Phannacometrics of pterostilbene: preclinical pharmacokinetics and metabolism, anticancer, antiinflammatory, antioxidant and analgesic activity. Phytother. Res., 2008, 22, 169-179.
26. Rimando A.M., Suh N.: Biological/chemopreventive activity of stilbenes and their effect on colon cancer. Planta Med., 2008, 74, 1635-1643.
27. Roupe K.A., Remsberg C.M., Yanez J.A. i wsp.: Phannacometrics of stilbenes: seguing towards the clinic. Curr. Clin. Pharmacol, 2006, 1, 81-101.
28. Roupe K.A., Yanez J.A., Teng X. W. i wsp.: Pharmacokinetics of selected stilbenes: rhapontigenin, piceatannol and pinosylvin in rats. J. Pharm. Pharmacol. 2006, 58, 1443-1450.
29. Saiko P., Szakmary A., Jaeger W. i wsp.: Resveratrol and its analogs: Defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutation Res., 2008, 658, 68094.
30. Sale S., Tunstall R.G., Ruparelia K.C. i wsp.: Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans3,4,5,4'-tetramethoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in human derived colon cancer cells. Int. J. Cancer, 2005, 115, 194-201.
31. Sengottuvelan M., Deeptha K., Nalini S.: Resveratrol ameliorates DNA damage, prooxidant and antioxidant imbalance in 1,2-dimethylhydrazine induced rat colon carcinogenesis. Chem. Biol. Interact. 2009, 181, 193-201.
32. Shakibaei M., Harikumar K.B., Aggarwal B.B.: Resveratrol addiction: to die or not to die. Mol. Nutr. Food Res., 2009, 53, 115-128.
33. Suh N., Paul S., Hao X. I wsp.: Pterostilbene, an active constituent of bluebenies, supresses aberrant crypt foci formation in the azoxymethane-induced colon carcinogenesis model In rats. Clin. Cancer Res., 2007, 13, 350-356.
34. Szaefer H., Cichocki M., Brauze D. i wsp.: Alteration in pase I and II enzyme activities and polycyclic aromatic hydrocarbons - DNA adduct formation by plant phenolics in mouse epidermis. Nutr. Cancer, 2004, 48, 70-77.
35. SzumiŁo J.: S̀rodki pochodzenia naturalnego w chemoprewencji raka pŁeskonablonkowego przeŁyku - badania doświadczalne. Pol. Merk. Lek., 2009, 26, 156-161.
36. Tolomeo M., Grimaudo S., Cristina A.D. i wsp.: Pterostilbene and 3'-hydroxypterostilbene are effective apoptosis-inducing agents in MDR and BCR-ABL-expressing leukemia cells. Int J. Biochem. Cell. Biol., 2005, 37, 1709-1726.
37. Walle T., Hsieh F., DeLegge M. i wsp.: High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos., 2004, 32: 1377-1382.
38. Wieder T., Prokop A., Bagci B.: Piceatannol, a hydroxylated analog of the chemoprotective agent resveratrol, is a pofenf inducer of apoptosis in the lymphoma cell line BJAB and primary leukemic lymphobiasts. Leukemia, 2001, 15, 1735-1742.
39. Zern T.L., Wood R.J., Greene C. i wsp.: Grape polyphenols exert cardioprotective effect in pre- and post-menopausal women by lowering plasma lipids and reducing oxidative stress. J. Nutr., 2005, 135, 1911-1917.
40. Zhou R., Fukui M., Choi H.J. i wsp.: Induction of a reversible, non-cytotoxic S-phase delay by resveratrol: implications for a mechanism of lifespan prolongation and cancer protection. Brit J. Pharmacol., 2009, 158, 462-474.